Egis Pharmaceuticals made a net profit of HUF 18,531 mil in 2012, up 36.4% when compared to the previous year. Historically, company's net profit reached an all time high of HUF 18,531 mil in 2012 and an all time low of HUF 5,540 mil in 2003.
This implies return on equity of 10.9% and return on invested capital of 14.1% in 2012. That is compared to 10.6% and 12.8% average seen in the last five years.
Since 2007, net profit of the firm increased by 76.7% or 12.1% a year on average.
As far as Egis Pharmaceuticals's peers are concerned, Gedeon Richter generated ROE of 9.76% and ROCE of 9.83% in 2012, Krka's profitability reached 13.4% and 11.1%, respectively. Sanofi-Aventis Czech Republic operated with 8.21% and 2.37% returns in 2012..